PuraPharm Corp Ltd Announces Key Developments

PuraPharm Corp Ltd, a pharmaceutical company specializing in traditional Chinese medicine, has recently made several announcements regarding its upcoming Annual General Meeting (AGM) and related shareholder communications. The company, listed on the Hong Kong Stock Exchange, is headquartered in Hong Kong.

Annual General Meeting and Shareholder Notifications

PuraPharm has issued a series of notifications to its shareholders in preparation for the AGM. On April 29, 2025, the company released a notice of the AGM, outlining key agenda items. These include the proposed re-election of retiring directors and the proposed grant of general mandates to buy back shares and issue new shares.

In addition to the AGM notice, PuraPharm has sent out notification letters to both registered and non-registered shareholders. These letters accompany the 2024 Annual Report and Circular, along with a proxy form for those unable to attend the meeting in person. The company has also provided a change request form for registered shareholders.

Financial Overview

As of April 24, 2025, PuraPharm’s share price closed at HKD 0.485. The company’s market capitalization stands at HKD 192,010,000. Over the past year, the stock has experienced significant volatility, with a 52-week high of HKD 0.85 on October 7, 2024, and a 52-week low of HKD 0.43 on April 15, 2025. The price-to-earnings ratio is currently -5.41, reflecting the company’s financial performance.

Company Profile

PuraPharm Corp Ltd is dedicated to the development of traditional Chinese medicine. For more information, stakeholders can visit the company’s website at www.purapharm.com/en/index.php .

These developments are crucial for shareholders as they prepare for the AGM and consider the company’s future direction and governance.